TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31227432
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg daily)
Study: 28282396
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine (FMP2.1/AS02A)
Study: 23658438
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg daily)
Study: 21542741
Drug: Leukotriene-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Leukotriene-receptor antagonist (LTRA)
Study: 30823952
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid
Study: 21542741
Drug: Long-acting beta(2)-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta(2)-agonist (LABA)
Study: 19542792
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 or 120 mg/d
Study: 12527545
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance interpersonal psychotherapy (IPT)
Study: 12527545
Drug: Monthly clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly clinical management and pill placebo
Study: 12527545
Drug: Supportive clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive clinical management and pill placebo
Study: 11755835
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% twice daily
Study: 8291420
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections of hyaluronan (placebo control: saline injections)
Study: 8291420
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole treatment
Study: 29457986
Drug: Oro-motor stimulation
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oro-motor stimulation for 5 min twice a day
Study: 24941841
Drug: Transcutaneous acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous acupoint electrical stimulation (TAES) combined with general intravenous anesthesia
Study: 24941841
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (control group)
Study: 20843301
Drug: Assertive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assertive intervention based on a modified version of the international model of assertive community treatment
Study: 16155276
Drug: +ISO (58
Approvals — FDA: no, EMA: no, PMDA: no
Description: +ISO (58 g protein powder/d containing 83 mg isoflavones/d)
Study: 16155276
Drug: -ISO (ethanol-extracted
Approvals — FDA: no, EMA: no, PMDA: no
Description: -ISO (ethanol-extracted soy-protein powder containing 3 mg isoflavones)
Study: 28912936
Drug: QSNYL-FEYL combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: QSNYL-FEYL combination
Study: 27488365
Drug: Morning ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning ingestion of warfarin
Study: 27488365
Drug: Evening ingestion
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening ingestion of warfarin (control)
Study: 25151492
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (EX) - 10min bouts of thrice‐weekly jumping plus capoeira
Study: 8314201
Drug: Bio‐Tropin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 8.00‐10.00 h (M group)
Study: 8314201
Drug: Bio‐Tropin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 14.00‐16.00 h (AN group)
Study: 8314201
Drug: Bio‐Tropin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 19.00‐21.00 h (NT group)
Study: 3302121
Drug: Budipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine (60 mg daily)
Study: 11883307
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (for vaginal hysterectomy)
Study: 27299457
Drug: SC peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC peginterferon β‐1a 125 mcg every-2-weeks
Study: 27299457
Drug: SC peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC peginterferon β‐1a 125 mcg every-4-weeks
Study: 22323410
Drug: Plasma 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma 25-hydroxyvitamin D (highest tertile, median concentration 30.1 ng/mL)
Study: 17367217
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Amoxicillin 1g + Metronidazole 500 mg + Bismuth subcitrate 240 mg twice daily for two weeks (Group A)
Study: 17367217
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Amoxicillin 1g + Furazolidone 200 mg twice daily + Bismuth subcitrate 240 mg twice daily for two weeks (Group B)
Study: 17367217
Drug: Furazolidone regimen
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone regimen for the first week followed by Omeprazole + Amoxicillin + Metronidazole + Bismuth subcitrate for the second week (Group C)
Study: 12188390
Drug: 1,400 mg
Normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,400 mg BID of saquinavir soft gel with zidovudine and lamivudine
Study: 12188390
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg TID of saquinavir soft gel with zidovudine and lamivudine
Study: 7586356
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg BID
Study: 7586356
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg TID
Study: 2177889
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 puffs à 2 mg)
Study: 7447172
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic treatment
Study: 31522845
Drug: Ranibizumab 0·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0·2 mg
Study: 31522845
Drug: Ranibizumab 0·1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0·1 mg
Study: 31522845
Drug: Ranibizumab 0·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0·2 mg vs Laser therapy
Study: 31522845
Drug: Ranibizumab 0·1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0·1 mg vs Laser therapy
Study: 31522845
Drug: Ranibizumab 0·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0·2 mg vs Ranibizumab 0·1 mg
Study: 26554707
Drug: Non-optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-optimal treatment (CT or IPT)
Study: 20499362
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment in postmenopausal women for 4 weeks
Study: 20499362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no estrogen treatment) in postmenopausal women (n = 18)
Study: 19302912
Drug: Naproxen sodium/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium/paracetamol 375/300 mg per 15 mL suspension
Study: 19302912
Drug: Naproxen sodium/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium/paracetamol 275/300 mg tablet
Study: 15114697
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered twice daily at 80, 100 or 120 mg/body/day for 28 days followed by 14 days of rest
Study: 11263760
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic drugs for Alzheimer's disease
Study: 9713009
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Study: 9713009
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Study: 2928433
Drug: Diazepam (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.14 mg/kg)
Study: 31734103
Drug: Cenobamate 200
Normalized name: cenobamate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 200 mg
Study: 30131425
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate magnesium (2.0 mEq/L) for 28 days
Study: 30131425
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate magnesium (1.0 mEq/L)
Study: 24264551
Drug: Gabapentin 15
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 15 mg.kg‐1 dissolved in 10 ml of saline orally 30 min. before induction of anesthesia
Study: 24264551
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of saline (Control)
Study: 19108793
Drug: OXN FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN FDC (10/5 mg, 20/10 mg, 40/20 mg)
Study: 19108793
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR 40 mg + Naloxone PR 20 mg
Study: 19108793
Drug: OXN FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN FDC 40/20 mg
Study: 19108793
Drug: Naloxone PR
Normalized name: naloxone Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone PR tablet 20 mg
Study: 19108793
Drug: OXN, Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN, Oxycodone PR, Naloxone PR
Study: 10781448
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% alone, 1.0 mL/kg
Study: 8227450
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg meclofenamate sodium bid
Study: 8227450
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg meclofenamate sodium bid
Study: 30998396
Drug: Genotype-guided antiplatelet
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided antiplatelet therapy
Study: 28069009
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy for 3 years
Study: 23712446
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg betamethasone intravenously
Study: 10959510
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (ligation or stripping)
Study: 19576645
Drug: High-dose concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose concurrent chemo-radiation followed by surgery
Study: 12040670
Drug: Concurrent chemo-radiation
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiation
Study: 10648315
Drug: Ephedrine 5
Normalized name: pseudoephedrine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 5 mg
Study: 353121
Drug: Cyclandelate 1600
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate 1600 mg daily
Study: 22561098
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy (mCIMT)
Study: 18400976
Drug: EP HIV-1090
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP HIV-1090 (DNA vaccine)
Study: 21838784
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg
Study: 14640387
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg
Study: 8648205
Drug: hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatitis B vaccine (control)
Study: 1465689
Drug: HCTZ‐A therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ‐A therapy (50 mg hydrochlorothiazide, 5 mg amiloride)
Study: 1465689
Drug: Pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (15 mg) plus HCTZ‐A
Study: 1465689
Drug: Nadolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (120 mg) plus HCTZ‐A
Study: 6463312
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methylphenidate (MPD)
Study: 6463312
Drug: Night after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night after 20 mg of methylphenidate (MPD) (N3)
Study: 23385795
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin
Study: 30652764
Drug: Topical azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical azithromycin
Study: 29951531
Drug: Norepinephrine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 5 μg/kg/h
Study: 29951531
Drug: Norepinephrine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 10 μg/kg/h
Study: 29951531
Drug: Norepinephrine 15
Normalized name: norepinephrine 0.15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 15 μg/kg/h
Study: 20736233
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg
Study: 20736233
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIAiv group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg given intravenously
Study: 10469687
Drug: Ganirelix (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (1.0 or 2.0 mg) administered once daily from stimulation day 6 onwards
Study: 10469687
Drug: Ganirelix (0.0625,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) administered during IVF cycles
Study: 31202686
Drug: Non-pharmacological interventions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological interventions targeting light exposure, fixed meal times, caffeine intake, and exercise; specific details on dosage and duration not provided.
Study: 28157726
Drug: β-Alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Alanine (BA) supplementation 6.4 g·d
Study: 26081010
Drug: Immediate face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate face-to-face cognitive behavioral therapy (FtF-CBT)
Study: 26081010
Drug: Stepped Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped Care treatment model (Psychoeducation, Internet-delivered CBT, and FtF-CBT)
Study: 26081010
Drug: Stepped Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped Care treatment model
Study: 24083670
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) administered intravenously after ex vivo culture expansion with autologous ischemic serum
Study: 11359590
Drug: Test 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 2: Detection of endtidal CO2 in the oral cavity
Study: 2843305
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg)
Study: 30574860
Drug: Enteral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day)
Study: 30574860
Drug: Sucrose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose placebo (same dose)
Study: 25843533
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg/0.20 mL injected into palpable cord
Study: 21030144
Drug: Duloxetine 80mg
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 80mg daily for 3 months
Study: 20126853
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone every three weeks (HR group)
Study: 20126853
Drug: Oral vitamins
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamins daily (HV and CV groups)
Study: 18046974
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg od (up-titrated to 60 mg od after 4 weeks in non-responders)
Study: 18046974
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg od (up-titrated to 40 mg od after 4 weeks in non-responders)
Study: 14762880
Drug: Concurrent chemoirradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoirradiation with cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with ifosfamide 1.4 g/m2, 5-fluorouracil 450 mg/m2, and leucovorin 20 mg/m2 daily for 5 days, repeated every 3 weeks for three cycles
Study: 14762880
Drug: Concurrent chemoirradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy
Study: 14762880
Drug: Concurrent chemoirradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoirradiation with cisplatin
Study: 11683693
Drug: OAAz (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAAz (amoxicillin 1000 mg b.d. and azithromycin 500 mg on day 1 and 250 mg on days 2-5)
Study: 11683693
Drug: OCM (clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (clarithromycin 250 mg b.d. and metronidazole 500 mg b.d.)
Study: 11683693
Drug: OBC (bacampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBC (bacampicillin 1200 mg b.d. and clarithromycin 500 mg b.d.)
Study: 11683693
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., and clarithromycin 500 mg b.d.)
Study: 9215782
Drug: Accelerated hyperfractionation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionation (AHF) - 0.89 Gy x 3 fractions/day; total dose 61.4 Gy
Study: 2168123
Drug: Oat-bran cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat-bran cereal diet (25 g oat bran/d)
Study: 704919
Drug: 11-Methyl 16,16
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-Methyl 16,16 Dimethyl Prostaglandin E2 (TM-PGE) administered orally at dosages of 2.5, 5, 7.5, and 10 microgram/kg
Study: 31314952
Drug: Nerve Growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve Growth Factor (NGF) injections (1 µg, 4 cm interval)
Study: 31314952
Drug: Control injections
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injections (isotonic-saline)
Study: 28716283
Drug: Dalfampridine extended
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine extended release (D-ER) 10mg tablets twice daily
Study: 25533024
Drug: Sapropterin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin therapy
Study: 18254805
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment based on silymarin/methylsulfonylmethane (S‐MSM) for 1 month
Study: 10807760
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol plus cyproterone acetate (CA)
Study: 10807760
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol plus CA
Study: 10807760
Drug: Oral CA
Normalized name: coral calx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CA alone
Study: 10807760
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone esters in transsexual females
Study: 10807760
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol plus CA
Study: 10807760
Drug: Parenteral testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral testosterone in females
Study: 9500129
Drug: Somnium (lorazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somnium (lorazepam 1 mg + diphenhydramine 25 mg)
Study: 9234051
Drug: lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (1 mg)
Study: 16368472
Drug: Conventional HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HRT (estradiol (E2) 2 mg/d during 12 days, E2 2 mg/d plus 1 mg/d of norethisterone acetate (NETA) during 10 days, E2 1 mg/d for 6 days)
Study: 16368472
Drug: Long-cycle HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-cycle HRT (two cycles with E2 2 mg/d during 28 days, followed by one cycle of conventional HRT and repeated every 3 months)
Study: 12830471
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy (1,000 mg daily, adapted to hemoglobin level)